Perianal fistulizing Crohn's disease: A call to action

被引:45
作者
Kamm, Michael A. [1 ]
Ng, Siew C. [1 ]
机构
[1] St Marks Hosp, Dept Gastroenterol, Harrow HA1 3UJ, Middx, England
关键词
D O I
10.1016/j.cgh.2007.10.010
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The advent of biological therapies has focused attention on the importance of healing luminal Crohn's disease, thereby modifying the disease course. Perianal fistulas are common in Crohn's disease and often have a poor prognosis, with permanent sphincter and perineal tissue destruction. The importance of healing these fistulas has been less well appreciated. Management still often is left in surgical hands alone, rather than the optimal combination of surgery, infection control, and immunosuppression. Drug therapy often is haphazard, and the means of assessing healing over a long time period has been characterized poorly. Recent studies have suggested that many of these patients can achieve fistula healing, at least in the medium term. We therefore call for more active intervention, with the goal of healing, in these sick patients. Perianal fistulas lead to substantial physical and emotional distress because of pain, discharge, incontinence, perineal and genital disfigurement, and slow resolution even with treatment. The advent of accurate anal imaging, improved knowledge of surgical outcomes, and potent biological therapies make it timely to reflect on current best-management strategies.
引用
收藏
页码:7 / 10
页数:4
相关论文
共 34 条
[1]
Genotype-phenotype analysis of the Crohn's disease susceptibility haplotype on chromosome 5q31 [J].
Armuzzi, A ;
Ahmad, T ;
Ling, KL ;
de Silva, A ;
Cullen, S ;
van Heel, D ;
Orchard, TR ;
Welsh, KI ;
Marshall, SE ;
Jewell, DP .
GUT, 2003, 52 (08) :1133-1139
[2]
Treatment of perianal fistulas in Crohn's disease by local injection of antibody to TNF-α accounts for a favourable clinical response in selected cases:: A pilot study [J].
Asteria, Corrado R. ;
Ficari, Ferdinado ;
Bagnoli, Siro ;
Milla, Monica ;
Tonelli, Francesco .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2006, 41 (09) :1064-1072
[3]
The clinical course of fistulating Crohn's disease [J].
Bell, SJ ;
Williams, AB ;
Wiesel, P ;
Wilkinson, K ;
Cohen, RCG ;
Kamm, MA .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 17 (09) :1145-1151
[4]
Response of fistulating Crohn's disease to infliximab treatment assessed by magnetic resonance imaging [J].
Bell, SJ ;
Halligan, S ;
Windsor, ACJ ;
Williams, AB ;
Wiesel, P ;
Kamm, MA .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 17 (03) :387-393
[5]
BERNSTEIN LH, 1980, GASTROENTEROLOGY, V79, P599
[6]
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial [J].
Colombel, Jean-Frederic ;
Sandborn, William J. ;
Rutgeerts, Paul ;
Enns, Robert ;
Hanauer, Stephen B. ;
Panaccione, Remo ;
Schreiber, Stefan ;
Byczkowski, Dan ;
Li, Ju ;
Kent, Jeffrey D. ;
Pollack, Paul F. .
GASTROENTEROLOGY, 2007, 132 (01) :52-65
[7]
LOWER GASTROINTESTINAL MALIGNANCY IN CROHNS-DISEASE [J].
CONNELL, WR ;
SHEFFIELD, JP ;
KAMM, MA ;
RITCHIE, JK ;
HAWLEY, PR ;
LENNARDJONES, JE .
GUT, 1994, 35 (03) :347-352
[8]
Thalidomide therapy for patients with refractory Crohn's disease: An open-label trial [J].
Ehrenpreis, ED ;
Kane, SV ;
Cohen, LB ;
Cohen, RD ;
Hanauer, SB .
GASTROENTEROLOGY, 1999, 117 (06) :1271-1277
[9]
Long-term oral tacrolimus therapy in refractory to infliximab fistulizing Crohn's disease [J].
González-Lama, Y ;
Abreu, L ;
Vera, MI ;
Pastrana, M ;
Tabernero, S ;
Revilla, J ;
Durán, JG ;
Escartin, P .
INFLAMMATORY BOWEL DISEASES, 2005, 11 (01) :8-15
[10]
FACTORS PREDICTIVE OF PERSISTENT OR RECURRENT CROHNS-DISEASE IN EXCLUDED RECTAL SEGMENTS [J].
GUILLEM, JG ;
ROBERTS, PL ;
MURRAY, JJ ;
COLLER, JA ;
VEIDENHEIMER, MC ;
SCHOETZ, DJ .
DISEASES OF THE COLON & RECTUM, 1992, 35 (08) :768-772